Skip to content

Leap/BeiGene initiate DKN-01+tislelizumab combo mid-stage study in gastric cancer

September 21, 2020

Leap Therapeutics (NASDAQ:LPTX) up 7.2% in premarket, and BeiGene, (NASDAQ:BGNE) have announced that first patient has been dosed in the DisTinGuish Phase 2a trial, evaluating Leap’s DKN-01, in combination with latter’s tislelizumab, with or without chemotherapy in patients with gastric or gastroesophageal junction cancer (G/GEJ).

The 72-subject trial is designed to evaluate safety, tolerability, and efficacy of the combination therapy of intravenous DKN-01 and tislelizumab ± CAPOX (capecitabine + oxaliplatin) in G/GEJ adenocarcinoma patients.

Leap is conducting this combination study in the U.S. as part of an exclusive license agreement with BeiGene.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: